“Preliminary Aggregate Safety And Immunogenicity Results From Three Trials Of A Purified Inactivated Zika Virus Vaccine Candidate: Phase 1, Randomised, Double-Blind, Placebo-Controlled Clinical Trials.”. Lancet 391 (10120). Lancet: 563-571. doi:10.1016/S0140-6736(17)33106-9.
. 2018. “Induction Of Hiv-1-Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 Hiv-1 Vaccination Of Humans.”. J Infect Dis 211 (4). J Infect Dis: 518-28. doi:10.1093/infdis/jiu485.
. 2015. “First-In-Human Evaluation Of A Hexon Chimeric Adenovirus Vector Expressing Hiv-1 Env (Ipcavd 002).”. J Infect Dis 210 (7). J Infect Dis: 1052-61. doi:10.1093/infdis/jiu217.
. 2014. “First-In-Human Evaluation Of The Safety And Immunogenicity Of A Recombinant Adenovirus Serotype 26 Hiv-1 Env Vaccine (Ipcavd 001).”. J Infect Dis 207 (2). J Infect Dis: 240-7. doi:10.1093/infdis/jis670.
. 2013. “Vaccine Protection Against Acquisition Of Neutralization-Resistant Siv Challenges In Rhesus Monkeys.”. Nature 482 (7383). Nature: 89-93. doi:10.1038/nature10766.
. 2012.